Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus  by Van Gaal, Luc et al.
Contents lists available at ScienceDirect
Journal of Clinical & Translational Endocrinology
journal homepage: www.elsevier .com/locate/ jcte
Journal of Clinical & Translational Endocrinology 1 (2014) 31e37Research PaperEfﬁcacy and safety of the glucagon-like peptide-1 receptor agonist
lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in
young (<50 years) obese patients with type 2 diabetes mellitusq
Luc Van Gaal a,*, Elisabeth Souhami b, Tianyue Zhou c, Ronnie Aronson d
aAntwerp University Hospital, Department of Endocrinology, Diabetology and Metabolic Diseases, Wilrijkstraat 10, B-2650 Edegem, Antwerp, Belgium
b Sanoﬁ, Paris, France
c Sanoﬁ, Bridgewater, NJ, USA
d LMC Diabetes & Endocrinology, Toronto, Ontario, Canadaa r t i c l e i n f o
Article history:
Received 8 January 2014
Received in revised form
11 March 2014
Accepted 23 March 2014
Previous presentations: This study was
presented as a poster at the 1st American
Diabetes Association Middle East Congress,
December 4e6, 2012, Dubai, UAE.
Keywords:
Glycated hemoglobin (HbA1c)
Body weight
Postprandial plasma glucose (PPG)Abbreviations: AE, adverse event; BMI, body ma
peptidase-4; FPG, fasting plasma glucose; GI, gastroint
peptide-1; HbA1c, glycated hemoglobin; LOCF, last obs
least squares; PPG, postprandial plasma glucose; T2D
TEAE, treatment-emergent adverse event.
q This is an open access article under the CC
creativecommons.org/licenses/by-nc-nd/3.0/).
Clinical Trial Registration Number: NCT00976937.
* Corresponding author. Tel.: þ32 3 821 32 66; fax:
E-mail address: Luc.VanGaal@uza.be (L. Van Gaal).
2214-6237/$ e see front matter  2014 The Authors.
http://dx.doi.org/10.1016/j.jcte.2014.03.001a b s t r a c t
Objective: To compare the efﬁcacy and safety of the once-daily prandial glucagon-like peptide-1 receptor
agonist lixisenatide with the dipeptidyl peptidase-4 inhibitor sitagliptin in patients aged <50 years
affected by obesity and type 2 diabetes mellitus (T2DM).
Materials and methods: This was a 24-week, double-blind, randomized, parallel-group study. Obese
patients with T2DM inadequately controlled on metformin were randomized to lixisenatide 20 mg once-
daily injection (n ¼ 158) or once-daily oral sitagliptin 100 mg (n ¼ 161). The primary endpoint was the
proportion of patients with a glycated hemoglobin (HbA1c) <7% and 5% weight loss at 24 weeks.
Results: The proportion of patients that achieved the primary endpoint was 12.0% for lixisenatide versus
7.5% for sitagliptin; weighted average of proportion difference: 4.6%, p ¼ 0.1696). A total of 40.7% of
patients achieved HbA1c <7% with lixisenatide versus 40.0% with sitagliptin. Lixisenatide produced
greater reductions in body weight (LS mean difference: 1.3 kg, p ¼ 0.0006) and postprandial plasma
glucose after a standardized meal test (LS mean difference: 34.4 mg/dL [1.9 mmol/L], p ¼ 0.0001)
versus sitagliptin. There was a similar incidence of treatment-emergent adverse events (63.9% vs. 60.9%)
and serious treatment-emergent adverse events (1.9% vs. 1.9%), with low rates of symptomatic hypo-
glycemia (0.6% vs. 1.9%) for lixisenatide and sitagliptin, respectively, and no cases of severe hypoglycemia.
Conclusion: In obese patients aged <50 years with T2DM, the proportion of patients with an HbA1c <7%
with weight loss 5% was similar between groups. Lixisenatide, however, resulted in signiﬁcantly greater
reductions in body weight and postprandial plasma glucose excursions than sitagliptin. Tolerability was
similar between groups.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
The prevalence of type 2 diabetes mellitus (T2DM) has increased
to epidemic proportions worldwide [1]. The rapid increase in new
cases of T2DM in people aged 30e39 years, and in children andss index; DPP-4, dipeptidyl
estinal; GLP-1, glucagon-like
ervation carried forward; LS,
M, type 2 diabetes mellitus;
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Published by Elsevier Inc. All righadolescents, is of particular concern [1]. In the USA, for example, the
prevalence of T2DM is expected to rise in people aged 30e39 years,
from 3.7% in 2001 to 5.2% in 2031 [2].
Obesity complicates the management of diabetes by increasing
insulin resistance and blood glucose concentrations [3]. Obesity is also
an independent risk factor for dyslipidemia, hypertension and cardio-
vascular disease [4e6]. There may be a relationship between body
mass index (BMI) andage at diagnosis of T2DM,with the risk of a T2DM
diagnosis rising continuously with increasing BMI [7]. The control of
body weight can be an important aspect of diabetes management and
it has been shown that moderate weight loss can improve insulin
sensitivity, decrease fasting plasma glucose (FPG) concentrations, and
reduce the need for diabetes medications [8,9]. However, weight loss
may not improve glycemic control in all obese patients with T2DM
[10,11] and a substantial proportion of patients who lose weight may
not have any reduction in plasma glucose levels [10].ts reserved.
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peptidase-4 (DPP-4) inhibitors are relatively recent additions to the
drugs available for the management of T2DM [12,13]. GLP-1 receptor
agonists work by mimicking the action of the endogenous incretin
GLP-1, which acts to control glycemia via several pathways, including
stimulation of insulin secretion, inhibition of glucagon secretion,
delay of gastric emptying and induction of satiety [12]. DPP-4 in-
hibitors work by inhibiting the DPP-4 enzyme that breaks downGLP-
1, thus prolonging the half-life of endogenous GLP-1; DPP-4 inhibitors
also augment gastric inhibitory polypeptide (GIP) signaling, which like
GLP-1 signaling, stimulates insulin release in the presence of elevated
glucose levels [12]. GLP-1 receptor agonists and DPP-4 inhibitors have
been demonstrated to reduce glycated hemoglobin (HbA1c). GLP-1
receptor agonists are generally associated with weight reduction and
DPP-4 inhibitors are usually weight neutral [13].
Lixisenatide is a once-daily prandial GLP-1 receptor agonist for
the treatment of T2DM. In a series of Phase III clinical trials known as
the GetGoal programme, lixisenatide produced reductions in HbA1c,
with a limited risk of hypoglycemia and beneﬁcial effects on body
weight as monotherapy, in combinationwith oral antidiabetic drugs,
and as add-on to basal insulin [14e20]. Lixisenatide was approved by
the European Medicines Agency in February 2013 for the treatment
of adults with T2DM in combinationwith oral antidiabetic drugs and/
or basal insulinwhen diet and exercise are not adequate. Sitagliptin is
the ﬁrst registered representative of the new class of DPP-4 inhibitors
for the treatment of patients with T2DM. The current study evaluated
the safety and efﬁcacy of lixisenatide compared with sitagliptin in a
young (<50 years of age), obese population with T2DM.
Methods
Study design
This study used a 24-week, double-blind, double-dummy, ran-
domized, active-controlled, two-arm, parallel-group trial design to
compare the efﬁcacy of lixisenatide with sitagliptin in obese
(BMI  30 kg/m2) patients with T2DM < 50 years of age, inade-
quately controlled on metformin. Patients were randomized to
lixisenatide 20 mg once-daily injection or oral sitagliptin 100 mg
once daily. All subjects provided written informed consent to
participate in the study.
Participants
Inclusion criteria included obese (BMI 30 kg/m2) patients with
T2DM, diagnosed at least 1 year before the screening visit, insufﬁ-
ciently controlled with metformin at a stable dose of at least 1.5 g/
day for at least 3months prior to screening, andwhowere aged18
to <50 years, with HbA1c 7.0% and 10% at screening. Exclusion
criteria included FPG at screening >250 mg/dL (>13.9 mmol/L);
history of unexplained pancreatitis, chronic pancreatitis, pancrea-
tectomy, stomach/gastric surgery, inﬂammatory bowel disease;
history of metabolic acidosis, including diabetic ketoacidosis within
1 year prior to screening; history of myocardial infarction, stroke, or
heart failure requiring hospitalization within 6 months prior to
screening; and amylase and/or lipase values of more than three
times the normal laboratory range.
Efﬁcacy and safety endpoints
The primary endpoint was a composite of the proportion of pa-
tients achieving HbA1c <7.0% and a body weight loss of at least 5% of
baseline body weight at Week 24. Secondary efﬁcacy assessments
included: change in HbA1c; the proportion of patients achieving
HbA1c <7.0%; change in body weight; FPG; change in 2-hpostprandial plasma glucose (PPG), glucose excursion, insulin, pro-
insulin, C-peptide, and glucagon after a standardized test meal; and
change in insulin resistance (assessed by homeostatic model assess-
ment [HOMA]-IR) and beta cell function (assessed by HOMA-b). A
post-hoc analysis based on the primary endpoint and the duration of
diabetes was undertaken to investigate the effect of the natural his-
tory phase of diabetes on the effectiveness of the study drugs.
The standardized meal was a 400 mL 600 kcal drink (Ensure
Plus Drink, Abbott Laboratories, Berkshire, UK) composed of 53.8%
carbohydrate, 16.7% protein and 29.5% fat. A central laboratory (Bio
Analytical Research Corporation) performed all clinical laboratory
assessments except for HbA1c, which was measured by a certiﬁed
level I National Glycohemoglobin Standardization Program central
laboratory. Reference range upper and lower limits for HbA1c were
4.0% and 6.0% and for FPG were 70 and 110 mg/dL (3.89 and
6.11 mmol/L), respectively. HbA1c was assessed via ion exchange
high-performance liquid chromatography (HPLC) measured using
the Tosoh G7 (Tessenderlo, Belgium) HPLC analyzer in the USA and
the Menarini (Firenze, Italy) 8160 chromatogram in the EU. Glucose
levels were measured using a hexokinase UV endpoint method on
the Roche Diagnostics (Indianapolis, IN, USA) Modular-P analyzer.
Proinsulin levels were assessed via Mercodia (Uppsala, Sweden)
enzyme-linked immunosorbent assay. Insulin and C-peptide were
measured using the Siemens (Erlangen, Germany) Immulite 2000
chemiluminescence assay system. Glucagonwas assessed using the
DPC (Los Angeles, CA, USA) Coat-A-Count radioimmunoassay.
Safety assessment included adverse events (AEs), treatment-
emergent AEs (TEAEs) and occurrence of symptomatic severe
hypoglycemia.
Statistical analysis
The safety population comprised all randomized patients who
were exposed to at least one dose of treatment. The efﬁcacy analyses
were performed on the modiﬁed intent-to-treat (mITT) population.
The primary analysis of the efﬁcacy variables at Week 24 was per-
formed based on measurements obtained during the 24-week on-
treatment period (before the rescue medication in the event of
rescue therapy), with last observation carried forward (LOCF) for
missingWeek 24 values. The primary efﬁcacy endpoint was analyzed
using a CochraneManteleHaenszel method stratiﬁed on randomi-
zation strata (screening HbA1c [<8.0%, 8.0%] and screening BMI
[<35 kg/m2, 35 kg/m2]). Data for all continuous secondary efﬁcacy
endpoints were analyzed by analysis of covariance with treatment
group, randomization strata (screening HbA1c and screening BMI)
and country asﬁxed effects and the corresponding baseline value as a
covariate. Sample size was determined based on the primary efﬁcacy
endpoint. A sample size of 300 (150 in each group) had 90% power to
demonstrate superiority of lixisenatide over sitagliptin with a 2-
sided test at 5% signiﬁcance level, assuming the percentage of pa-
tients deﬁned as responders on HbA1c (<7%) and weight (at least 5%
loss) was 25% with lixisenatide (based on a 13-week dose-ranging
study of lixisenatide [21]) and 10% with sitagliptin.
Diabetes duration tertiles were based on a complete diabetes
duration dataset with equal patient distribution: <2.2 years (1st
tertile),2.2 to<4.8 years (2nd tertile), and4.8 years (3rd tertile).
Tertiles were used to assess percent of patients who had both HbA1c
<7% and body weight loss 5% at the end of treatment.
Results
Patients
A total of 620 patients were screened and 319 patients were
randomized to one of the two treatment groups (n ¼ 158 for
Table 1
Baseline characteristics (safety population)
Mean values Lixisenatide
n ¼ 158
Sitagliptin
n ¼ 161
Male, % 34.8 45.3
Race, %
Caucasian 83.5 78.9
Black 5.1 6.8
Asian 0.6 0.6
Other 10.8 13.7
Age, years (SD) 42.7 (5.2) 43.4 (4.7)
Diabetes duration, years
Mean (SD) 4.4 (3.9) 4.4 (3.6)
Median (min, max) 3.2 (1.0, 29.6) 3.4 (1.0, 19.6)
MET, daily dose, mg (SD) 1985 (414) 1937 (405)
HbA1c, % (SD) 8.16 (0.89) 8.1 (1.0)
HbA1c by diabetes duration, % (SD)a
<2 years 8.02 (0.71) 8.02 (0.87)
2.2 to <4.8 years 8.24 (0.70) 8.23 (0.79)
4.8 years 8.56 (0.91) 8.48 (0.87)
2-h PPG
mg/dL (SD) 247.9 (68.0) 250.6 (71.8)
mmol/L (SD) 13.8 (3.8) 13.9 (4.0)
Glucose excursion
mg/dL (SD) 78.7 (47.5) 80.6 (46.6)
mmol/L (SD) 4.4 (2.6) 4.5 (2.6)
FPG
mg/dL (SD) 163.6 (46.8) 161.3 (46.6)
mmol/L (SD) 9.1 (2.6) 9.0 (2.6)
BMI, kg/m2 (SD) 36.8 (7.3) 36.8 (6.3)
Body weight, kg (SD) 98.5 (23.5) 100.6 (23.8)
SD ¼ standard deviation; MET ¼ metformin; HbA1c ¼ glycated hemoglobin;
PPG¼ postprandial plasma glucose; FPG¼ fasting plasma glucose; BMI¼ bodymass
index.
a Intention-to-treat population with baseline HbA1c 7%.
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patients were exposed to the study treatment and included in the
analyses. During the 24-week treatment period, 8.5% of patients
(n ¼ 27/319) discontinued from the study (10.1% [n¼ 16/158] in the
lixisenatide group and 6.8% [n ¼ 11/161] in the sitagliptin group),
primarily due to nonspeciﬁc causes listed by investigators as ‘other
reasons’ (4.4% in the lixisenatide group vs. 3.1% in the sitagliptin
group).
Patient demographics and clinical characteristics were generally
similar between the two groups (Table 1), although the lixisenatide
group had a lower proportion of male patients (35% vs. 45% with
sitagliptin).Figure 1. HbA1c <7% and weight loss of 5% (mITT population). The proportion of
patients achieving the primary endpoint of HbA1c <7% and weight loss of 5% of
baseline body weight at Week 24. HbA1c ¼ glycated hemoglobin; mITT ¼ modiﬁed
intent-to-treat; NS ¼ not signiﬁcant; CI ¼ conﬁdence interval.Glycated hemoglobin and body weight
A greater proportion of patients met the criteria for the primary
endpoint of HbA1c <7% with weight loss of 5% in the lixisenatide
group than in the sitagliptin group (12.0% vs. 7.5%, respectively)
with a weighted average of proportion difference for lixisenatide
versus sitagliptin (95% conﬁdence interval [CI]) of 4.6% (1.8, 11.0),
p ¼ 0.1696 (Figure 1).
A similar proportion of patients in each treatment group ach-
ieved HbA1c <7% (40.7% for lixisenatide vs. 40.0% for sitagliptin;
weighted average of proportion difference for lixisenatide vs. sita-
gliptin [95% CI]: 0.8% [9.7, 11.3]; p ¼ 0.884) (Figure 2A).
Least squares (LS) mean change from baseline in HbA1c was
similar for lixisenatide and sitagliptin (LS mean change  standard
error [SE]: 0.7%  0.1 vs. 0.7%  0.1, respectively; LS mean dif-
ference vs. sitagliptin [95% CI]: 0.1% [0.2, 0.3]; p ¼ 0.6042).
Lixisenatide therapy was associated with greater reductions in
body weight versus sitagliptin over the 24-week study period (LS
mean change: 2.5 kg for lixisenatide vs. 1.2 kg for sitagliptin; LSmean difference vs. sitagliptin at Week 24 [95% CI]: 1.3 kg
[2.1, 0.6], p ¼ 0.0006) (Figure 2B).
Postprandial plasma glucose
Lixisenatide-treated subjects also showed signiﬁcantly
greater reductions in 2-h PPG. LS mean change from
baseline  SE: 60.3  6.8 mg/dL (3.4  0.4 mmol/L)
and 25.9  6.9 mg/dL (1.4  0.4 mmol/L) for lixisenatide and
sitagliptin, respectively (LS mean difference: 34.4 mg/dL; 95%
CI 51.8, 17.0 mg/dL [1.9 mmol/L; 95% CI 2.9, 0.9 mmol/L];
p ¼ 0.0001; Figure 3A), and glucose excursion. LS mean change
from baseline  SE: 45.9  4.9 mg/dL (2.6  0.3 mmol/L)
and 7.6  5.0 mg/dL (0.4  0.3 mmol/L) for lixisenatide and
sitagliptin, respectively (LS mean difference: 38.3 mg/dL; 95%
CI 50.8, 25.8 mg/dL [2.1 mmol/L; 95% CI 2.8, 1.4 mmol/L];
p < 0.0001; Figure 3B), after a standardized meal test versus
sitagliptin.
Fasting plasma glucose
Therewere no signiﬁcant differences in changes in FPG between
groups (LS mean change  SE: 8.1  3.5 mg/dL [0.5  0.2 mmol/
L] for lixisenatide vs. 12.54  3.6 mg/dL [0.7  0.2 mmol/L] for
sitagliptin; LS mean difference  SE vs. sitagliptin: 4.4  4.6 mg/dL;
95% CI 4.6, 13.4 mg/dL [0.3  0.3 mmol/L; 95% CI 0.3, 0.7 mmol/
L]; p ¼ 0.3342).
Insulin, pro-insulin, C-peptide and glucagon
There were no signiﬁcant differences between the two groups
in changes in fasting plasma insulin (LS mean difference for lix-
isenatide vs. sitagliptin: 0.1 mU/mL), pro-insulin (0.4 mU/mL), C-
peptide (0.03 ng/mL) or glucagon (1.63 pg/mL).
Insulin resistance and beta cell function
No signiﬁcant differences were observed between lixisenatide
and sitagliptin in terms of their effect on insulin resistance or beta-
cell function. Week 24 LS mean  SE change from baseline in
HOMA-IR was 0.52  0.37 and 0.57  0.38 with lixisenatide and
sitagliptin, respectively (LS mean difference 0.05; 95% CI 0.82,
0.92). Week 24 LS mean  SE change from baseline in HOMA-bwas
Figure 3. PPG and glucose excursion (mITT population). LS mean change  SE from
baseline in (A) 2-h PPG and (B) glucose excursion after a standardized meal test at
Week 24. PPG ¼ postprandial plasma glucose; mITT ¼ modiﬁed intent-to-treat;
LS ¼ least squares; SE ¼ standard error.
Figure 2. HbA1c <7% and body weight (mITT population). (A) The proportion of pa-
tients achieving a target HbA1c <7% at Week 24; (B) LS mean change from baseline in
body weight (kg)  SE at Week 24. HbA1c ¼ glycated hemoglobin; mITT ¼ modiﬁed
intent-to-treat; LS ¼ least squares; CI ¼ conﬁdence interval; SE ¼ standard error.
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respectively (LS mean difference 0.13; 95% CI 23.1, 22.8).
Safety
There was a similar incidence of TEAEs and serious TEAEs for
lixisenatide and sitagliptin (Table 2). The percentage of patients
with TEAEs leading to treatment discontinuation was low and was
similar between the groups (2.5% for lixisenatide and 3.1% for
sitagliptin). Gastrointestinal (GI) disorders were slightly more
frequent for lixisenatide than sitagliptin, with nausea being the
most frequently reported GI event in the lixisenatide group. Only
one patient discontinued treatment due to nausea, vomiting, diar-
rhea and abdominal pain. There was a low rate of symptomatic
hypoglycemia in both groups, 0.6% for lixisenatide and 1.9% for
sitagliptin, and no cases of severe hypoglycemia. No cases of
conﬁrmed pancreatitis were observed and one case of calcitonin
increase was seen in the sitagliptin arm (Table 2).
Post-hoc analyses
A tertile post-hoc analysis was conducted to investigate the ef-
fect of the natural history of diabetes. The ﬁndings showed that a
similar percentage of patients treated with lixisenatide achievedthe composite primary endpoint of HbA1c<7% and weight loss5%
across all tertiles of diabetes duration (10.9%, 14.4% and 11.1% at
<2.2 years, 2.2e4.8 years and 4.8 years, respectively). In contrast,
sitagliptin appeared to be more effective in patients with a duration
of diabetes <2.2 years (12.7%, 5.5% and 3.9% across the respective
diabetes duration tertiles) (Figure 4).
Discussion
With the rising prevalence of T2DM in younger people [1,2], the
evaluation of new antidiabetic drugs in younger populations is
increasingly important. In this study, both a GLP-1 receptor agonist,
namely lixisenatide, and a DPP-4 inhibitor, sitagliptin, demon-
strated efﬁcacy in leading patients to an HbA1c of <7.0% with a
concomitant reduction in body weight of at least 5% at the end of
the study. Results from the post-hoc analyses, however, suggest that
lixisenatide treatment may be more beneﬁcial than sitagliptin
treatment in patients with a relatively longer diabetes duration.
Lixisenatide treatment resulted in greater reductions in body
weight compared with sitagliptin. These results are in line with
previous reports that DPP-4 inhibitors are body weight neutral
while treatment with GLP-1 RAs confers body weight beneﬁts [13],
and are consistent with previous trials of lixisenatide in combina-
tion with metformin [15,17]. Differing body weight changes with
these medications are due to their distinct mechanisms of action.
GLP-1 RAs augment the incretin hormone GLP-1, which has a role in
Table 2
Adverse events (safety population)
Adverse event, n (%) Lixisenatide
n ¼ 158
Sitagliptin
n ¼ 161
Any TEAE 101 (63.9) 98 (60.9)
Any serious TEAE 3 (1.9) 3 (1.9)
Death 0 0
Discontinuation due to TEAE 4 (2.5) 5 (3.1)
Discontinuation due to nausea and vomiting 1 (0.6) 0
Treatment-emergent GI disorders 48 (30.4) 34 (21.1)
Most common TEAEs
Nausea 28 (17.7) 11 (6.8)
Headache 20 (12.7) 15 (9.3)
Diarrhea 14 (8.9) 12 (7.5)
Vomiting 7 (4.4) 0
Conﬁrmed diagnosis of pancreatitis 0 0
Calcitonin increase 0 1 (0.6)
Treatment-emergent symptomatic hypoglycemiaa 1 (0.6) 3 (1.9)
Blood glucose <60 mg/dL (<3.3 mmol/L) 1 (0.6) 1 (0.6)
Severe symptomatic hypoglycemiab 0 0
Blood glucose <36 mg/dL (<2.0 mmol/L) 0 0
TEAE ¼ treatment-emergent adverse event; GI ¼ gastrointestinal.
a Event with clinical symptoms with either plasma glucose <60 mg/dL
(<3.3 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or
glucagon administration if no plasma glucose value was available.
b Symptomatic hypoglycemia in which the patient required the assistance of
another person and one of the following: plasma glucose <36 mg/dL (<2.0 mmol/L)
or prompt recovery after oral carbohydrate, intravenous glucose or glucagon
administration if no plasma glucose value was available.
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emptying. Like GLP-1 RAs, DPP-4 inhibitors also augment GLP-1;
however, in contrast with GLP-1 RAs, DPP-4 inhibitors also
augment GIP signaling. GIP does not reduce food intake and also
facilitates gastric emptying, which shortens the duration of satiety.
Therefore co-augmentation of these two incretin hormones by
DPP-4 inhibitors may cancel out their effects on body weight,
resulting in weight neutrality [22]. Nevertheless, weight loss has
important additional health beneﬁts in patients with diabetes as itFigure 4. A post-hoc analysis of HbA1c <7% and weight loss 5% according to baseline diabe
to-treat; NS ¼ not signiﬁcant. aResponse rate differences versus sitagliptin at Week 24. Anaimproves risk factors for cardiovascular disease by decreasing blood
pressure, improving serum lipid concentrations and reducing
serum markers of inﬂammation, and shows a positive association
with incretin-induced glucose lowering [23,24]; consequently,
weight loss is recommended for all overweight or obese adults with
T2DM [24,25]. Signiﬁcant body weight beneﬁts with lixisenatide in
the absence of signiﬁcant differences compared with sitagliptin in
terms of C-peptide and fasting plasma glucose appear to be coun-
terintuitive. However, the insulin-independent effects of lixisena-
tide (i.e. slowed gastric emptying) and the differing incretin
hormone augmentation proﬁles of the two medications provide
some explanation for this apparent paradox. In addition, weight
loss may not consistently improve glycemic control in obese pa-
tients with T2DM [10,11].
Lixisenatide demonstrated a signiﬁcantly greater reduction in
PPG after a standardized meal test compared with sitagliptin: these
results are consistent with previous lixisenatide studies that
demonstrate robust PPG reduction with lixisenatide treatment
across the various stages of the natural history of the disease
[14,16e20]. Postprandial hyperglycemia may be an independent
risk factor for cardiovascular events, and glycemic variability may
have a more deleterious effect than sustained hyperglycemia in the
development of diabetic complications [26,27]. Furthermore, the
postprandial contribution to hyperglycemia has been described as
pivotal to achievement of optimal glycemic control both when
HbA1c approaches target levels [28] and when fasting plasma
glucose has already reached acceptable control [29]. As a result, PPG
is now recognized as a key therapeutic target for improving gly-
cemic control in patients with T2DM.
One limitation of the present study is the patient population,
which was limited to patients affected by T2DM and obesity and a
relatively young age (<50 years). Participants had a mean age, BMI
and median diabetes duration of 43 years, 36.8 kg/m2 and 3.2e3.3
years, respectively, which could be considered a proxy for a rela-
tively early stage of the disease. In this population, beta-cell func-
tion may still be relatively normal [30]. Interestingly, lixisenatidetes duration (mITT population). HbA1c ¼ glycated hemoglobin; mITT ¼modiﬁed intent-
lysis was carried out on crude rates using a chi-square test of difference in rates.
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beta-cell function [31], and in special populations such as elderly
patients [32]. In contrast to long-acting, non-prandial GLP-1
receptor agonists, which predominantly reduce FPG levels by
stimulating insulin secretion from pancreatic beta-cells [33], short-
acting, or prandial, agents such as lixisenatide primarily lower PPG
via deceleration of gastric emptying [33,34]. As a result, lixisenatide
may be beneﬁcial in patients with relatively low beta-cell function,
such as older patients and/or those with a longer duration of dia-
betes. In the dose-ranging study [21] used to estimate the lix-
isenatide primary endpoint responder rate for the power
calculation in the present study, patients were older (55e57 years)
and had longer mean duration of disease (6e7 years), with >60% of
patients achieving HbA1c <7% with lixisenatide 20 mg once daily. As
stated above, lixisenatide may be more beneﬁcial than sitagliptin in
patients with longer disease duration. It is possible, therefore, that
the patient characteristics (relatively young with earlier disease) in
the current study were partly responsible for the overestimation of
lixisenatide efﬁcacy; if the patient population had been older with
more advanced disease, response rates with lixisenatide may have
been closer to those observed in the dose ranging study.
In this study, lixisenatide and sitagliptin demonstrated similar
tolerability proﬁles with similar rates of overall AEs and discontin-
uations due to AEs. In general, DPP-4 inhibitors demonstrate slightly
better tolerability proﬁles than GLP-1 receptor agonists, particularly
in terms of GI disorders. In our study, however, GI disorders were
only slightly more frequent with lixisenatide than with sitagliptin.
In conclusion, this study demonstrated that the GLP-1 receptor
agonist lixisenatide had a favorable safety proﬁle and was well
tolerated in obese adults aged <50 years with T2DM. Lixisenatide
was as effective in reducing HbA1c as the DPP-4 inhibitor sitagliptin,
with the additional advantage of greater reductions in body weight
and PPG excursions after a test meal, accompanied by a similar
incidence of AEs (and consequent discontinuation) as well as
symptomatic hypoglycemia.
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